Alecensa reduced risk of disease progression or death in Alk-positive metastatic NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In follow-up data from the phase III ALEX study, an initial treatment Alecensa (alectinib) significantly reduced the risk of disease progression or death by 57 percent (hazard ratio= 0.43, 95 percent CI: 0.32-0.58) compared to crizotinib after two years of follow-up in people with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, as assessed by the investigator.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.

Login